-+ 0.00%
-+ 0.00%
-+ 0.00%

Chardan Capital Maintains Buy on Ocular Therapeutix, Maintains $21 Price Target

Benzinga·11/05/2025 12:42:34
Listen to the news
Chardan Capital analyst Daniil Gataulin maintains Ocular Therapeutix (NASDAQ:OCUL) with a Buy and maintains $21 price target.